U.S. Health Officials Defend Rejection of Moderna’s Flu Vaccine

February 11, 2026 - 21:53

Senior U.S. health officials have publicly defended the Food and Drug Administration's recent choice not to review Moderna's application for its new mRNA-based flu vaccine. The decision, which effectively halted the shot's path to market this year, has sparked significant debate within the medical community.

The agency cited insufficient data on the vaccine's effectiveness, particularly concerning certain circulating flu strains, as the primary reason for the rejection. This move surprised many doctors and public health experts who had anticipated a faster authorization process, similar to the pathway used for COVID-19 vaccines. They argue that new vaccine technologies are critically needed to improve upon the modest effectiveness rates of traditional seasonal flu shots.

Internally, the decision was reportedly divisive, with some officials advocating for a more flexible review given the platform's proven success against COVID-19. However, leaders have emphasized that the established regulatory standards for influenza vaccines, which are judged on their specific strain match and performance, must be rigorously upheld regardless of the technology platform. Officials stated that Moderna is expected to conduct further studies and may resubmit its application with more comprehensive data in the future. The situation underscores the ongoing balancing act between accelerating innovative medical solutions and adhering to long-standing safety and efficacy protocols.